Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI
Authors' conclusion
Empagliflozin improved HF outcomes similarly in patients after AMI with or without type 2 diabetes or chronic kidney disease.
Study context
- Population
- Patients after acute MI with or without T2DM and/or CKD3,489 (53%) without T2DM/CKD
- Participants
- 6,522 patients
- Comparison
- Empagliflozin vs placebo, by T2DM/CKD status
- Primary endpoint
- HF events (HHF and AEs of HF) by T2DM/CKD status; trial primary endpoint all-cause mortality or HHF
Primary result
As reported in the abstract
Total HHF, by T2DM/CKD subgroup
Empagliflozin vs PlaceboRelative risk (95% CI)P value
Without T2DM or CKD: 50vs 63 HHF; 1.74vs 2.31 events per 100 patient-years
0.75(0.48–1.18)
With T2DM or CKD: 98vs 144 HHF; 3.91vs 6.04 events per 100 patient-years
0.65(0.45–0.94)
P = 0.61for interactionFurther findings
Primary endpoint (all-cause mortality or hospitalization for heart failure (HHF)), by subgroup
- No differences observed
Safety
Any adverse event (AEs), serious AEs, AEs leading to permanent drug discontinuation
- Similar between treatment groups in both subgroups
Original publication
Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI. ESC Heart Fail. Published 14 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →